Everolimus: all 667 studies that test it

Page 2 of 7. Open to participants first (47), then studies with results posted, then the rest; newest registration first within each.

• REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategyCompletedNCT02115113Phase 3Results posted
• Novartis Everolimus TransitionCompletedNCT02096107Phase 4Results posted
• Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast CancerCompletedNCT02069093Phase 2Results posted
• Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With SurgeryTerminatedNCT02031536Phase 2Results posted
• Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.CompletedNCT02017860Phase 2Results posted
• Comparing Everolimus and Sirolimus in Renal Transplant RecipientsCompletedNCT01976390Not applicableResults posted
• Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.CompletedNCT01936519Not applicableResults posted
• Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® InductionCompletedNCT01935128Phase 4Results posted
• NECTAR Everolimus Plus Cisplatin in Triple (-) Breast CancerCompletedNCT01931163Phase 2Results posted
• Rapalogues for Autism Phenotype in TSC: A Feasibility StudyCompletedNCT01929642Phase 2Results posted
• Role of Everolimus in Highly Sensitized PatientsCompletedNCT01911546Phase 2Results posted
• A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD KidneysTerminatedNCT01878786Phase 2/3Results posted
• 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant PatientsCompletedNCT01843348Phase 3Results posted
• MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene VariationsCompletedNCT01827384Phase 2Results posted
• A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial CarcinomaCompletedNCT01797523Phase 2Results posted
• Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AICompletedNCT01797120Phase 2Results posted
• Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.CompletedNCT01789281Phase 4Results posted
• VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine TumorsTerminatedNCT01784861Phase 1/2Results posted
• A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.CompletedNCT01783444Phase 2Results posted
• An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker AnalysisCompletedNCT01743560Phase 4Results posted
• PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in ChildrenCompletedNCT01734512Phase 2Results posted
• A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset SeizuresCompletedNCT01713946Phase 3Results posted
• Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast CancerCompletedNCT01698918Phase 2Results posted
• Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate SodiumCompletedNCT01680861Phase 3Results posted
• Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine TumorsCompletedNCT01678664Phase 2Results posted
• S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast CancerActive, not recruitingNCT01674140Phase 3Results posted
• SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath TumorsCompletedNCT01661283Phase 2Results posted
• Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive RegimensCompletedNCT01653847Not applicableResults posted
• Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)CompletedNCT01642186Phase 2Results posted
• Everolimus in Treating Cutaneous T-cell LymphomaTerminatedNCT01637090Phase 2Results posted
• The Everolimus-Transplant Exit Strategy Trial (E-TEST)TerminatedNCT01636466Phase 3Results posted
• Exemestane-RAD001-MetforminTerminatedNCT01627067Phase 2Results posted
• A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant RecipientsCompletedNCT01625377Phase 3Results posted
• Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant RecipientsCompletedNCT01624948Phase 4Results posted
• Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)CompletedNCT01596062Phase 2Results posted
• An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)CompletedNCT01595009Phase 4Results posted
• Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic CancerCompletedNCT01582191Phase 1Results posted
• Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib TosylateTerminatedNCT01582009Phase 1/2Results posted
• 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA TrialCompletedNCT01563354Phase 2Results posted
• Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant RecipientsCompletedNCT01551212Phase 4Results posted
• Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant RecipientsCompletedNCT01544491Phase 3Results posted
• Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)CompletedNCT01524783Phase 3Results posted
• Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or PazopanibCompletedNCT01514448Phase 4Results posted
• Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast CancerTerminatedNCT01499160Phase 2Results posted
• Everolimus as Second-line Therapy in Metastatic Renal Cell CarcinomaCompletedNCT01491672Phase 2Results posted
• Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular CarcinomaCompletedNCT01488487Phase 2Results posted
• Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) ToxicityTerminatedNCT01473732Not applicableResults posted
• Phase I-II Everolimus and Sorafenib in Recurrent High-Grade GliomasCompletedNCT01434602Phase 1/2Results posted
• Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2CompletedNCT01419639Phase 2Results posted
• Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant RecipientsCompletedNCT01404325Phase 3Results posted
• Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)CompletedNCT01399918Phase 2Results posted
• Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCCTerminatedNCT01379521Phase 2Results posted
• GSK1120212 Rollover StudyTerminatedNCT01376310Phase 2Results posted
• Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)TerminatedNCT01365468Phase 2Results posted
• RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine DifferentiationCompletedNCT01317615Phase 4Results posted
• Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate CancerTerminatedNCT01313559Phase 2Results posted
• A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain MetastasesCompletedNCT01305941Phase 2Results posted
• Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)CompletedNCT01289912Phase 2Results posted
• A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck CancerCompletedNCT01283334Phase 1/2Results posted
• Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue SarcomaCompletedNCT01281865Phase 1/2Results posted
• A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast CancerTerminatedNCT01272141Phase 2Results posted
• Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid CancerCompletedNCT01270321Phase 2Results posted
• SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) AvoidanceCompletedNCT01266148Phase 4Results posted
• RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the BladderCompletedNCT01259063Phase 1/2Results posted
• RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal MelanomaCompletedNCT01252251Phase 2Results posted
• Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal TransplantCompletedNCT01239472Phase 4Results posted
• Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney CancerTerminatedNCT01239342Phase 2Results posted
• Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast CancerCompletedNCT01231659Phase 2Results posted
• Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal CancerCompletedNCT01231399Phase 1/2Results posted
• Study of Everolimus (RAD001) in Combination With LenalidomideCompletedNCT01218555Phase 1Results posted
• A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.CompletedNCT01206764Phase 4Results posted
• Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell CarcinomaTerminatedNCT01185366Phase 2Results posted
• Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial CancerCompletedNCT01184326Phase 1Results posted
• 24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant RecipientsCompletedNCT01169701Phase 4Results posted
• Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade GliomasCompletedNCT01158651Phase 2Results posted
• Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal CancerCompletedNCT01154335Phase 1Results posted
• Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant RecipientsCompletedNCT01150097Phase 3Results posted
• Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon CancersTerminatedNCT01149434Phase 1/2Results posted
• A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted TreatmentCompletedNCT01136733Phase 1/2Results posted
• Study in Locally Advanced Squamous Cell Carcinoma of Head and NeckTerminatedNCT01133678Phase 2Results posted
• RAD001 Plus Carboplatin in Breast Cancer PatientsCompletedNCT01127763Phase 2Results posted
• S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone SurgeryCompletedNCT01120249Phase 3Results posted
• A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid TumorsTerminatedNCT01115803Phase 1Results posted
• Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant RecipientsCompletedNCT01114529Phase 3Results posted
• Everolimus Versus Placebo in Head and Neck CancerTerminatedNCT01111058Phase 2Results posted
• Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell CarcinomaCompletedNCT01108445Phase 2Results posted
• Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant RecipientsCompletedNCT01079143Phase 3Results posted
• Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaCompletedNCT01075321Phase 1/2Results posted
• Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)CompletedNCT01070316Phase 1/2Results posted
• Letrozole and RAD001 With Advanced or Recurrent Endometrial CancerActive, not recruitingNCT01068249Phase 2Results posted
• Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT01062399Phase 1/2Results posted
• A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With LymphangioleiomyomatosisCompletedNCT01059318Phase 2Results posted
• RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal CancerCompletedNCT01058655Phase 1/2Results posted
• RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck CancerTerminatedNCT01057277Phase 1Results posted
• Phase II Study of RAD001 Head and Neck CancerTerminatedNCT01051791Phase 2Results posted
• Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After DocetaxelCompletedNCT01051570Phase 2Results posted
• Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal SarcomasTerminatedNCT01048723Phase 2Results posted
• RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal CarcinomaCompletedNCT01047293Phase 1/2Results posted
• Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.CompletedNCT01035229Phase 3Results posted
• BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell CarcinomaCompletedNCT01034631Phase 1/2Results posted

← Everolimus overview